Early dialogue key to securing pharma partnerships
This article was originally published in Scrip
Executive Summary
Constructive early-stage discussions between large pharma companies and small biotech firms are key to forming the alliances critical to both, licensing executives said at last week's BioTrinity conference hosted by the Oxfordshire Bioscience Network in Newbury, UK.